New hope for PNH patients: experimental drug OMS906 shows promise in early trial
NCT ID NCT05972967
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a new drug called OMS906 in 12 adults with paroxysmal nocturnal hemoglobinuria (PNH) who were not getting enough benefit from the standard treatment ravulizumab. The goal was to see if OMS906 is safe and can improve hemoglobin levels. Participants received OMS906 every 8 weeks, and researchers monitored side effects and blood counts.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PAROXYSMAL NOCTURNAL HEMOGLOBINURIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Omeros Investigational Site
Aachen, Germany
-
Omeros Investigational Site
Ulm, Germany
-
Omeros Investigational Site
Thessaloniki, Greece
-
Omeros Investigational Site
Lausanne, Switzerland
-
Omeros Investigational Site
Leeds, United Kingdom
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A pill that could replace infusions for a rare blood disease?
- Every-8-Week shot could simplify PNH treatment
- Real-World test: can a targeted drug keep PNH in check for years?
- New transplant method aims to reduce complications in bone marrow failure patients
- No treatment, just observation: large study looks at PNH blood cells
- New hope for rare blood disorder: Long-Term study of XH-S003 underway